Abstract

Over the last decade, the field of chirality has witnessed revolutionary changes with increased emphasis placed on delineation of enantioselective pharmacology, pharmacokinetics and pharmacodynamics. Indeed, there are numerous examples in the literature, which confirm the benefits of recognizing chirality in a drug entity. Based on the current data, therefore, it is important not to ignore chirality of the molecule during the drug development process. lnspite of lack of special regulatory requirements, it appears to be prudent to evaluate very early in the development, the pharmacologic, pharmacokinetic, pharmacodynamic, and toxicologic profiles of the racemate and the individual enantiomers to justify the development of any one form of the chiral drug for human use. In this context, the present article emphasis the impact of chirality in the pharmacokinetic disposition of racemic drugs.